Literature DB >> 28293695

[Molecular-allergological aspects of allergen-specific immunotherapy].

Uta Jappe1,2.   

Abstract

Allergen-specific immunotherapy (SIT) does not achieve 100% efficacy, nor is there a reliable marker for therapy failure. However, advances in molecular allergology over the past few years have allowed a significantly improved characterization of the patients using molecular-allergological analysis methods (molecular phenotyping). Thus, major and minor allergens can be identified. In addition, the marker allergens for the severity of an allergic reaction, the pathological and therapeutic predictive marker allergens, and sensitization patterns are identified.

Entities:  

Keywords:  Biomarker; Desensitization, immunologic; Major allergens; Marker allergens; Minor allergens

Mesh:

Substances:

Year:  2017        PMID: 28293695     DOI: 10.1007/s00105-017-3958-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  43 in total

Review 1.  Pitfalls in double-blind, placebo-controlled oral food challenges.

Authors:  B Niggemann; K Beyer
Journal:  Allergy       Date:  2007-07       Impact factor: 13.146

2.  Profilin: a relevant aeroallergen?

Authors:  Mónica Ruiz-García; Manuela García Del Potro; Mar Fernández-Nieto; Domingo Barber; Lucía Jimeno-Nogales; Joaquín Sastre
Journal:  J Allergy Clin Immunol       Date:  2011-03-31       Impact factor: 10.793

Review 3.  Component-resolved diagnosis-assisted prescription of allergen-specific immunotherapy: a practical guide.

Authors:  R Asero
Journal:  Eur Ann Allergy Clin Immunol       Date:  2012-10

4.  Component resolution reveals additional major allergens in patients with honeybee venom allergy.

Authors:  Julian Köhler; Simon Blank; Sabine Müller; Frank Bantleon; Marcel Frick; Johannes Huss-Marp; Jonas Lidholm; Edzard Spillner; Thilo Jakob
Journal:  J Allergy Clin Immunol       Date:  2014-01-17       Impact factor: 10.793

5.  [Recombinant allergens. For routine use or still only science?].

Authors:  P Schmid-Grendelmeier
Journal:  Hautarzt       Date:  2010-11       Impact factor: 0.751

6.  BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.

Authors:  R Treudler; A Franke; A Schmiedeknecht; B Ballmer-Weber; M Worm; T Werfel; U Jappe; T Biedermann; J Schmitt; R Brehler; A Kleinheinz; J Kleine-Tebbe; H Brüning; F Ruëff; J Ring; J Saloga; K Schäkel; T Holzhauser; S Vieths; J C Simon
Journal:  Allergy       Date:  2017-01-17       Impact factor: 13.146

7.  A protocol for oral desensitization in children with IgE-mediated cow's milk allergy.

Authors:  P Meglio; E Bartone; M Plantamura; E Arabito; P G Giampietro
Journal:  Allergy       Date:  2004-09       Impact factor: 13.146

8.  Recombinant phospholipase A1 (Ves v 1) from yellow jacket venom for improved diagnosis of hymenoptera venom hypersensitivity.

Authors:  Henning Seismann; Simon Blank; Liliana Cifuentes; Ingke Braren; Reinhard Bredehorst; Thomas Grunwald; Markus Ollert; Edzard Spillner
Journal:  Clin Mol Allergy       Date:  2010-04-01

9.  Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges.

Authors:  S T H P Bolhaar; M M Tiemessen; L Zuidmeer; A van Leeuwen; K Hoffmann-Sommergruber; C A F M Bruijnzeel-Koomen; L S Taams; E F Knol; E van Hoffen; R van Ree; A C Knulst
Journal:  Clin Exp Allergy       Date:  2004-05       Impact factor: 5.018

10.  Predictive values of component-specific IgE for the outcome of peanut and hazelnut food challenges in children.

Authors:  K Beyer; L Grabenhenrich; M Härtl; A Beder; B Kalb; M Ziegert; A Finger; N Harandi; R Schlags; M Gappa; L Puzzo; H Röblitz; M Millner-Uhlemann; S Büsing; H Ott; L Lange; B Niggemann
Journal:  Allergy       Date:  2014-11-30       Impact factor: 13.146

View more
  1 in total

Review 1.  Relevance of Lipophilic Allergens in Food Allergy Diagnosis.

Authors:  Uta Jappe; Christian Schwager
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-09       Impact factor: 4.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.